University of Iowa Research Foundation

Galera Labs, LLC

University of Michigan

Douglas R Spitz, Jr

Michael K Schultz

Dennis Patrick Riley

Robert A Beardsley

Mark E Anderson

Melissa Fath

Somya Kapoor

Peter J Mohler

Collin Heer

Jeffrey Robert Erickson

Max S Wicha

Jeffery L Keene

Aliasger Karimjee Salem

Bryan G Allen

Fenghuang Zhan

Yueming Zhu

Olha M Koval

Duane D Hall

Frederick E Domann

Amaraporn Wongrakpanich

Mei-ling A Joiner

Nukhet Aykin-Burns

Kyle Kloepping

Joshua Schoenfeld

Joseph Cullen

Garry R Buettner

Melissa A Fath

A method of treating cancer in a subject includes administering at least one active agent including one or more of a thioredoxin reductase inhibitor and a glutathione depleting agent, and administering a pentaaza macrocyclic ring complex corresponding to formula (I) below:

Combination therapy for cancer treatment

A method of treating cancer in a subject includes administering an active agent selected from ascorbic acid, an ascorbic acid derivative, and/or a pharmaceutically acceptable salt thereof and administering a pentaaza macrocyclic ring complex corresponding to formula (I) below:

Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

Compositions and methods for treating cancer

A method of treating cancer in a subject includes administering an active agent selected from ascorbic acid, an ascorbic acid derivative, and/or a pharmaceutically acceptable salt thereof and administering a pentaaza macrocyclic ring complex corresponding to formula (I) below: 

The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form HO, and one or more anti-cancer therapies.

Compositions and methods for cancer therapy

The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria ('an XTPP agent') or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.

Compositions and methods of treating cancer

Disclosed are compositions and methods for treating or preventing diseases or disorders associated with mitochondrial CaMKII activity.

Mitochondrial-targeted cationic nanoparticles comprising CaMKII inhibitors and uses thereof for treating and preventing diseases and disorders associated with CaMKII activity

Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.

Methods of detecting oxidized calcium/calmodulin dependent protein kinase II

Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II

Growing community of inventors

Iowa City, IA, United States of America

Douglas R Spitz, Jr